CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...
Zacks.com on MSN1d
Axsome Stock Surges 20% on Auvelity Patent Settlement With TevaShares of Axsome Therapeutics AXSM jumped 20.2% on Monday after the company announced that it has entered into a settlement ...
Investor's Business Daily on MSN14d
Teva Stock Dives 14%. Why Its CEO Says It's A Victim.Teva stock fell early Wednesday after the pharma giant reported adjusted earnings of 71 cents per share on $4.23 billion in fourth-quarter sales. Please watch the video at Investors.com - How To Buy ...
Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...
Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...
Teva has not raised capital since it acquired Actavis from Allergan in 2016 - a deal worth nearly $40 billion and for which ...
Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.
Sanofi, AstraZeneca and two leading trade groups want clarity around an appellate decision that called for Teva to delist ...
Teva, a global pharmaceutical leader, to install the SaverOne System across its entire fleet of 50 delivery trucks in Israel Petah Tikvah, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- SaverOne 2014 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback